Optimization of Recombinant Human Interferon-Gamma Expression and Purification in E. coli, and Developing an Immunization Protocol for the Production of Optimal Humoral Response
Biologics: Targets and Therapy · 2026-04 · Volume 20 · 1-15
DOI: 10.2147/btt.s584180 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Biologics: Targets and Therapy, 2026-04. Verfasst von Vanessa Uwituze und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Science, Mount Kigali University, Kigali, Rwanda. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Recombinant human interferon gamma (rhIFN-γ) and monoclonal antibodies are promising biomolecules for improving clinical medicines worldwide due to their biomedical applications. However, most African countries lack established production protocols. Although Freund's Complete Adjuvant (FCA) has been widely used to enhance antibody production, it has been reported to cause adverse effects. This study aimed to optimize the expression and purification of rhIFNγ and develop an immunization protocol for producing optimal humoral responses using alternative adjuvants such as RIBI Immunochem (RIBI) adjuvant and Freund's Incomplete Adjuvant (FIA), with FCA as the standard. Methodology: BL-21, and protein expression was induced with IPTG. The expression and purification conditions were optimized. To evaluate immunization regimens and alternative adjuvants to FCA, three groups of female BALB/c mice were immunized with varying concentrations of rhIFNγ (25, 50, and 100 µg) mixed with an equal volume of RIBI adjuvant, FIA, and FCA. An Enzyme-Linked Immunosorbent Assay was used to measure antibody levels from each group.
Results
The study identified 0.6 mM of IPTG at 37°C and 250 rpm for 4 hours as the optimal conditions for rhIFNγ expression. Increasing imidazole concentration in wash and elution buffers enhanced rhIFNγ purity but reduced protein yield. Administration of 100 µg of rhIFNγ with RIBI adjuvant elicited a sufficient immune response, while higher concentrations of FCA and FIA increased side effects, indicating the need for lower adjuvant doses.
Conclusion
Although FCA has been reported to produce high antibody titers with notable side effects, this study found no significant difference in antibody levels between mice immunized with 100 µg rhIFNγ mixed with FCA and the group immunized with 100 µg rhIFNγ plus RIBI adjuvant.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratory Science, Mount Kigali University, Kigali, Rwanda.
- Department of Biotechnical and Diagnostic Sciences, Makerere University, Kampala, Uganda.
- Research, Innovation, and Data Science Division, Rwanda Biomedical Center, Kigali, Rwanda.
- Department of Science, Technical, and Vocational Education, Makerere University, Kampala, Uganda.
ORCID-Profile: David Paul Nalumenya, Kenneth Ssekatawa, Charles Drago Kato
Zitieren
APA
Uwituze, V., Mugasa, C. M., Namayanja, M., Nalumenya, D. P., Ndayisenga, J., Ssekatawa, K., & Kato, C. D. (2026). Optimization of Recombinant Human Interferon-Gamma Expression and Purification in E. coli, and Developing an Immunization Protocol for the Production of Optimal Humoral Response. Biologics: Targets and Therapy, Volume 20, 1-15. https://doi.org/10.2147/btt.s584180
Vancouver
Uwituze V, Mugasa CM, Namayanja M, Nalumenya DP, Ndayisenga J, Ssekatawa K, et al. Optimization of Recombinant Human Interferon-Gamma Expression and Purification in E. coli, and Developing an Immunization Protocol for the Production of Optimal Humoral Response. Biologics: Targets and Therapy. 2026;Volume 20:1-15. doi:10.2147/btt.s584180
BibTeX
@article{Uwituze2026,
author = {Uwituze, Vanessa and Mugasa, Claire M and Namayanja, Monica and Nalumenya, David Paul and Ndayisenga, Jerome and Ssekatawa, Kenneth and Kato, Charles Drago},
title = {Optimization of Recombinant Human Interferon-Gamma Expression and Purification in E. coli, and Developing an Immunization Protocol for the Production of Optimal Humoral Response},
journal = {Biologics: Targets and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--15},
doi = {10.2147/btt.s584180}
}
EUVIMED